To do the study, researchers in the United Kingdom identified 22, women age 40 and older who were diagnosed with Type 2 diabetes and had been treated with either:. On average, the women received between five and six prescriptions for the type of insulin they were being treated with per year. The risk of breast cancer started to increase 5 years after the women started being treated with insulin glargine and after they had filled more than 30 prescriptions of insulin glargine.
Compared to women treated with NPH insulin, the researchers found no increase in breast cancer risk among women treated with insulin detemir. Still, the number of women treated with insulin detemir in the study was small, so the results might have been different if there were more data. The researchers said the data suggest that the risk of breast cancer was higher among women who had previously used insulin glargine, but not for new users of insulin.
Still, the number of new insulin users in the study also was small, so these results also might have been different if there were more data. Other research suggests that diabetic women taking the medicine metformin brand names: Fortamet, Glucophage, Glumetza, Riomet , which is commonly used to treat Type 2 diabetes, have a lower-than-average risk of breast cancer. If you have Type 2 diabetes, you may want to talk to your endocrinologist about this study.
If you use insulin glargine to manage the diabetes, it might make sense to ask your doctors if another type of insulin or metformin could be a better choice for you.
Together, you and your doctors can figure out the best way to manage the diabetes and keep your risk of breast cancer as low as it can be. Create a profile for better recommendations. Breast implant illness BII is a term that some women and doctors use to refer to a wide range FDA is continuing to work with the manufacturer of Lantus and the U.
Department of Veterans Affairs VA to further evaluate the long-term risk, if any, for cancer associated with the use of Lantus. At this time, FDA has not concluded that Lantus increases the risk of cancer. Our review is ongoing, including review of information from a current clinical trial, and the Agency will update the public when it has additional information. This communication is in keeping with FDA's commitment to inform the public about its ongoing safety review of drugs.
The duration of patient follow-up in all four studies was shorter than what is generally considered necessary to evaluate cancer risk from drug exposure. Also, the four studies provided limited information on patients' use of insulin products.
Additionally, some of these studies did not take into account whether the patients used any anti-diabetic drugs before the study time period or whether there were any changes in how patients used these drugs during the study period. Furthermore, risk factors for cancer, such as smoking, family history of cancer, and obesity, may not have been adequately controlled for in these studies.
This prevents our ability to attribute the observed cancer risk solely to Lantus. A post-hoc evaluation examining the data after the trial concluded for outcomes that were not identified a priori of the occurrence of cancer was conducted.
The safety population consisted of over patients per treatment arm with a median exposure of approximately five years. The overall occurrence of all cancers was 5.
0コメント